[1]康晓娜,赵丽华,卢春燕.哈森十三味丸联合来曲唑片治疗激素依赖型乳腺癌临床观察[J].西部中医药,2022,35(08):66-69.[doi:10.12174/j.issn.2096-9600.2022.08.16]
　KANG Xiaona,ZHAO Lihua,LU Chunyan.Clinical Observation on Hasen 13-ingredient Pills and Letrozol Tablets in the Treatment of Hormone-dependent Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2022,35(08):66-69.[doi:10.12174/j.issn.2096-9600.2022.08.16]
点击复制

哈森十三味丸联合来曲唑片治疗激素依赖型乳腺癌临床观察
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年08期
页码:
66-69
栏目:
民族医药
出版日期:
2022-08-15

文章信息/Info

Title:
Clinical Observation on Hasen 13-ingredient Pills and Letrozol Tablets in the Treatment of Hormone-dependent Breast Cancer
作者:
康晓娜1, 赵丽华1, 卢春燕2
1.内蒙古自治区国际蒙医医院，内蒙古 呼和浩特 010065
2.内蒙古自治区中医医院
Author(s):
KANG Xiaona1, ZHAO Lihua1, LU Chunyan2
1.Inner Mongolia Autonomous Region International Hospital of Mongolian medicine, Hohehot 010065, China
2.Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine
关键词:
乳腺癌; 激素依赖型; 哈森十三味丸; 细胞因子; 来曲唑片
Keywords:
breast cancer;  hormone-dependent; 13-ingredient pills; cytokines; letrozol tablets
分类号:
R737.9
DOI:
10.12174/j.issn.2096-9600.2022.08.16
摘要:
目的探讨哈森十三味丸联合来曲唑片治疗激素依赖型乳腺癌的临床疗效及对相关细胞因子水平的影响。 方法选择激素依赖型乳腺癌患者100例，按照随机数字表法分为对照组和观察组，每组50例。观察组采用哈森十三味丸联合来曲唑片联合治疗，对照组采用来曲唑片治疗，两组患者均治疗1个月。观察两组月经变化、无进展生存期（progression-free survival，PFS）、临床疗效、总体生存率；检测血清肿瘤坏死因子（tumor necrosis factor α，TNF-α）、白细胞介素8（interleukin 8，IL-8）、白细胞介素6（interleukin 6，IL-6）、雌二醇（estradiol，E2）、促卵泡生成激素（follicle stimulating hormone，FSH）、中性粒细胞与淋巴细胞比率（neutrophil-lymphocyte ratio，NLR）、血小板与淋巴细胞比率（platelet-to-lymphocyte ratio，PLR）等指标变化。 结果观察组总有效率及总体生存率均高于对照组（P＜0.05）。观察组PFS显著长于对照组（P＜0.05），观察组闭经发生率低于对照组（P＜0.05），经期紊乱和经量减少情况的发生率与对照组比较差异无统计学意义（P＞0.05）。治疗后观察组血清TNF-α、IL-8、IL-6、NLR、PLR水平均低于对照组（P＜0.05），血清E2、FSH水平高于对照组（P＜0.05）。 结论与来曲唑单药治疗比较，以哈森十三味丸联合来曲唑片治疗激素依赖型乳腺癌，可提高临床效果，优化细胞因子及相关指标水平。
Abstract:
ObjectiveTo explore clinical effects of Hasen 13-ingredient pills and letrozol tablets in the treatment of hormone-dependent breast cancer and its influence on the levels of the related cytokines. MethodsAll 100 patients were chosen, divided into the control group and the observation group in light of random number method, 50 cases in each group. The observation group was treated by Hasen 13-ingredient pills and letrozol tablets, and the control group by letrozol tablets, both groups were treated for one month. To observe menstrual changes, PFS, clinical effects, overall survival rate between both groups; to detect the changes of the indexes including TNF-α, IL-8, IL-6, E2, FSH, NLR and PLR in the serum. ResultsThe observation group was higher than the control group in total effective rate and overall survival rate (P<0.05). PFS of the observation group was significantly longer than that of the control group (P<0.05), the incidence of amenorrhea of the observa-tion group was lower than that of the control group (P<0.05), the difference had no statistical meaning when compared with the control group in the incidences of menstrual disorders and reduced menstrual volume (P>0.05). After the treatment, the observation group was lower than the control group in the levels of serum TNF-α, IL-8, IL-6, NLR and PLR (P<0.05), higher than the control group in the levels of E2 and FSH (P<0.05). ConclusionCompared with letrozol tablets, treating hormone-dependent breast cancer by Hasen 13-ingredient pills and letrozol tablets could raise clinical effects, and optimize the levels of cell factors and the related indexes.

相似文献/References:

[1]王斌,王艳杰,梁贵文,等.乳积方防治乳腺癌患者术后复发转移的临床研究*[J].西部中医药,2013,26(08):101.
　WANG Bin,WANG Yanjie,LIANG Guiwen,et al.Clinical Study on RuJiFang to Prevent Postoperative Recurrence and Metastasis of Breast Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):101.
[2]侯俊明,江静.疏肝解郁法联合化疗治疗乳腺癌临床疗效分析[J].西部中医药,2014,27(09):1.
[3]王丽,何丽娟,朱玉芹.循证护理对乳腺癌化疗患者自尊水平和应对方式的影响[J].西部中医药,2014,27(11):134.
[4]朱慧华.纽曼护理对乳腺癌手术患者心理健康和生活质量的影响[J].西部中医药,2014,27(12):105.
[5]张晓华,张晓岚△,梁玉荣,等.综合心理干预对乳腺癌化疗患者医学应对方式及生命质量的影响[J].西部中医药,2015,28(07):123.
[6]谷雨,华海清△.中医辨证分型与乳腺癌预后的相关性研究[J].西部中医药,2015,28(04):85.
[7]刘琛,吴黎雅,赵红佳,等.人参养荣汤干预乳腺癌新辅助化疗所致气血两虚证的临床研究[J].西部中医药,2011,24(11):3.
[8]李树建.扶正祛积汤联合CEF化疗方案治疗晚期乳腺癌40例临床研究[J].西部中医药,2013,26(09):1.
　LI Shujian.Clinical Study on FuZheng QuJiTang Combined with CEF Chemotherapy in Treating 40 Patients Suffering from Advanced Mammary Cancer[J].Western Journal of Traditional Chinese Medicine,2013,26(08):1.
[9]安妮,杨俊兰.消 疒徵祛积方联合化疗对晚期乳腺癌患者血清CEA、CA125、CA153和CA19-9含量及临床疗效的影响[J].西部中医药,2013,26(03):7.
　AN Ni,YANG Junlan.Effects of XiaoZhen QuJiFang and Chemotherapy on Clinical Efficacy and Contents of Serum CEA, CA125, CA153 and CA19-9 of Patients with Mammary Cancer at Advanced Stage[J].Western Journal of Traditional Chinese Medicine,2013,26(08):7.
[10]朱竹华,许敏菊,张汀荣,等.以家庭为中心的护理模式在完全植入式静脉输液港乳腺癌化疗患者中的应用[J].西部中医药,2016,29(03):114.
　ZHU Zhuhua,XU Minju,ZHANG Dingrong,et al.FCC Applying to Breast Cancer Patients Who Received Chemotherapy by TIVAP[J].Western Journal of Traditional Chinese Medicine,2016,29(08):114.

备注/Memo

备注/Memo:
康晓娜（1985—），女，主管药师。研究方向：临床药学、药物分析。内蒙古自治区卫生和计划生育委员会2017年度科研计划项目（201703052）。
更新日期/Last Update: 2022-08-15